TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients

NCT ID: NCT00345592

Last Updated: 2017-03-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Demonstrate the efficacy of the device-based managed therapy to treat atrial tachycardia and fibrillation (AT/AF) in patients with CHF indication for implant of a CRT defibrillator and to demonstrate the advantage of automatic electrical therapy of atrial arrhythmias compared to an in-hospital approach for treatment of symptomatic AT/AF.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Congestive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device managed arm

Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.

Group Type EXPERIMENTAL

Dual (atrial and ventricular) implantable defibrillator

Intervention Type DEVICE

The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.

Traditional arm

Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.

Group Type ACTIVE_COMPARATOR

Dual (atrial and ventricular) implantable defibrillator

Intervention Type DEVICE

In hospital application of anti arrhythmic therapies via the device

Dual (atrial and ventricular) implantable defibrillator

Intervention Type DEVICE

Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual (atrial and ventricular) implantable defibrillator

The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.

Intervention Type DEVICE

Dual (atrial and ventricular) implantable defibrillator

In hospital application of anti arrhythmic therapies via the device

Intervention Type DEVICE

Dual (atrial and ventricular) implantable defibrillator

Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chronic symptomatic HF despite stable, optimal drug therapy
* indication for a cardiac resynchronisation device with defibrillator backup according to current guidelines
* patients implanted with cardiac resynchronization device with dual (atrial and ventricular) defibrillation capabilities

Exclusion Criteria

* Chronic atrial fibrillation
* Valvular disease
* patients who underwent or are planned for ablation of atrial fibrillation
* cerebral vascular accident/transient ischemic attack within 12 months from implant which lead to relevant impairment
* preexisting unipolar pacemaker
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gianluca Botto, MD

Role: PRINCIPAL_INVESTIGATOR

Azienda Ospedale S. Anna

Luigi Padeletti, MD

Role: PRINCIPAL_INVESTIGATOR

Istituto di Clinica Medica I° e Cardiologia A.O.C. Careggi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istituto di Clinica Medica I° e Cardiologia A.O.C.

Careggi, , Italy

Site Status

Azienda Ospedale S. Anna

San Fermo Della Battaglia (CO), , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Botto GL, Boriani G, Favale S, Landolina M, Molon G, Tondo C, Biffi M, Grandinetti G, De Filippo P, Raciti G, Padeletti L. Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial. Trials. 2011 Feb 15;12:44. doi: 10.1186/1745-6215-12-44.

Reference Type DERIVED
PMID: 21324118 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2005_TH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cologne Cardioversion Study
NCT02241382 COMPLETED NA